全文获取类型
| 收费全文 | 4469篇 |
| 免费 | 269篇 |
| 国内免费 | 9篇 |
专业分类
| 耳鼻咽喉 | 23篇 |
| 儿科学 | 421篇 |
| 妇产科学 | 161篇 |
| 基础医学 | 534篇 |
| 口腔科学 | 128篇 |
| 临床医学 | 255篇 |
| 内科学 | 1081篇 |
| 皮肤病学 | 109篇 |
| 神经病学 | 207篇 |
| 特种医学 | 133篇 |
| 外科学 | 591篇 |
| 综合类 | 142篇 |
| 一般理论 | 1篇 |
| 预防医学 | 215篇 |
| 眼科学 | 115篇 |
| 药学 | 238篇 |
| 中国医学 | 6篇 |
| 肿瘤学 | 387篇 |
出版年
| 2023年 | 35篇 |
| 2022年 | 92篇 |
| 2021年 | 149篇 |
| 2020年 | 81篇 |
| 2019年 | 117篇 |
| 2018年 | 152篇 |
| 2017年 | 104篇 |
| 2016年 | 155篇 |
| 2015年 | 149篇 |
| 2014年 | 189篇 |
| 2013年 | 235篇 |
| 2012年 | 368篇 |
| 2011年 | 360篇 |
| 2010年 | 209篇 |
| 2009年 | 139篇 |
| 2008年 | 255篇 |
| 2007年 | 283篇 |
| 2006年 | 212篇 |
| 2005年 | 201篇 |
| 2004年 | 179篇 |
| 2003年 | 155篇 |
| 2002年 | 168篇 |
| 2001年 | 92篇 |
| 2000年 | 108篇 |
| 1999年 | 78篇 |
| 1998年 | 41篇 |
| 1997年 | 29篇 |
| 1996年 | 22篇 |
| 1995年 | 22篇 |
| 1994年 | 20篇 |
| 1993年 | 14篇 |
| 1992年 | 36篇 |
| 1991年 | 47篇 |
| 1990年 | 24篇 |
| 1989年 | 39篇 |
| 1988年 | 22篇 |
| 1987年 | 24篇 |
| 1986年 | 16篇 |
| 1985年 | 15篇 |
| 1984年 | 12篇 |
| 1983年 | 14篇 |
| 1981年 | 6篇 |
| 1980年 | 6篇 |
| 1979年 | 5篇 |
| 1977年 | 5篇 |
| 1976年 | 11篇 |
| 1975年 | 4篇 |
| 1974年 | 5篇 |
| 1972年 | 7篇 |
| 1971年 | 5篇 |
排序方式： 共有4747条查询结果，搜索用时 15 毫秒
991.
992.
993.
James Chih-Hsin Yang Shirish M. Gadgeel Lecia VanDam Sequist Chien-Liang Wu Vassiliki A. Papadimitrakopoulou Wu-Chou Su Joseph Fiore Sanatan Saraf Harry Raftopoulos Amita Patnaik 《Journal of thoracic oncology》2019,14(3):553-559
Introduction
Anti-EGFR agents are standard treatments for patients with EGFR-mutant advanced NSCLC. The feasibility of combining erlotinib or gefitinib with the anti–programmed death 1 immunotherapy pembrolizumab was evaluated in the phase 1/2 KEYNOTE-021 study (NCT02039674).Methods
Adults with previously untreated stage IIIB/IV EGFR-mutant NSCLC were treated with pembrolizumab 2 mg/kg intravenously every 3 weeks plus oral erlotinib 150 mg daily in cohort E or oral gefitinib 250 mg daily in cohort F, using a 3 + 3 design with cohort expansion. rTumor response was evaluated per Response Evaluation Criteria in Solid Tumors version 1.1 by blinded independent central review. The primary objective was determination of a recommended phase 2 dose.Results
Twelve patients enrolled to receive pembrolizumab plus erlotinib and seven to receive pembrolizumab plus gefitinib. No dose-limiting toxicities or grade 5 events occurred. Pembrolizumab plus erlotinib was feasible, with adverse events similar to those expected for monotherapy. However, pembrolizumab plus gefitinib was not feasible due to grade 3/4 liver toxicity in five of seven patients (71.4%), leading to permanent treatment discontinuation in four patients. The most frequently occurring treatment-related adverse events with pembrolizumab plus erlotinib were rash (50.0%), dermatitis acneiform, diarrhea, hypothyroidism, and pruritus (33.3% each). The objective response rate was 41.7%, including response in all four patients with programmed death ligand 1 expression 50% or greater.Conclusions
Although pembrolizumab plus gefitinib was not feasible, the toxicity profile observed with pembrolizumab plus erlotinib suggests combining immunotherapy with anti-EGFR therapy is feasible. Pembrolizumab plus erlotinib did not improve objective response rate compared with previous monotherapy studies; further evaluation would be necessary to evaluate potential effects on other efficacy outcomes. 相似文献994.
Mina Lee Haemin Hong Won Kim Li Zhang Terence W. Friedlander Lawrence Fong Amy M. Lin Eric J. Small Xiao X. Wei Tammy J. Rodvelt Brigid Miralda Brian Stocksdale Charles J. Ryan Rahul Aggarwal 《Clinical genitourinary cancer》2019,17(1):e92-e96
Background
Patients with biochemically recurrent prostate cancer and short prostate-specific antigen doubling time (PSADT) are at risk for metastasis yet may wish to avoid androgen deprivation therapy. Itraconazole may have antitumor activity without affecting circulating androgen levels. We therefore evaluated itraconazole as a potentially noncastrating treatment approach in biochemically recurrent prostate cancer.Patients and Methods
Patients with biochemically recurrent prostate cancer and PSADT ≤ 15 months, with serum testosterone > 150 ng/dL, were prospectively enrolled. The primary end point was the proportion of patients who experienced ≥ 50% decline from baseline in serum prostate-specific antigen (PSA) by week 12.Results
Twenty-one patients were enrolled. The median (range) age, baseline PSA, and PSADT at study entry was 72 (49-76) years, 7.6 (1.5-45.5) ng/mL, and 5.7 (1.2-13.0) months, respectively. Among 19 patients with evaluable data, 1 patient (5%) had a > 50% PSA decline. Nine patients (47%) experienced any PSA decline (mean decline 25.0%, range 2%-60%) by week 12. Among 10 patients without a PSA decline, the on-treatment versus pretreatment PSADT was not significantly longer (median 6.8 vs. 4.3 months, P = .17). There was no significant change from baseline to week 12 in serum testosterone (median change = 32.4%, P = .21) or androstenedione (median change = ?8.3%, P = .85). The most common adverse events were edema (52%), fatigue (38%), hypertension (24%), and hypokalemia (24%).Conclusion
Itraconazole modulates serum PSA levels without lowering serum testosterone. However, the magnitude of effect is modest, and treatment carries risk of toxicities associated with mineralocorticoid excess. 相似文献995.
Developing Innovative,Robust and Affordable Medical Linear Accelerators for Challenging Environments
M. Dosanjh A. Aggarwal D. Pistenmaa E. Amankwaa-Frempong D. Angal-Kalinin S. Boogert D. Brown M. Carlone P. Collier L. Court A. Di Meglio J. Van Dyk S. Grover D.A. Jaffray C. Jamieson J. Khader I. Konoplev H. Makwani C.N. Coleman 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(6):352-355
996.
Kari Yacisin Sharon Balter Annie Fine Don Weiss Joel Ackelsberg David Prezant Ross Wilson David Starr Jennifer Rakeman Marisa Raphael Celia Quinn Amita Toprani Nancy Clark Nathan Link Demetre Daskalakis Aletha Maybank Marcelle Layton Jay K. Varma 《MMWR. Morbidity and mortality weekly report》2015,64(12):321-323
997.
Phacomatosis pigmentovascularis type 2b (phacomatosis cesioflammea) with double superior vena cava,abdominal varicosities,and natal tooth: Novel associations 
下载免费PDF全文
下载免费PDF全文 Archana Singal MD Hema Mittal MD Anju Aggarwal MD Saurabhi Das MD Smita Manchanda MD 《Pediatric dermatology》2018,35(3):e151-e154
Phacomatosis pigmentovascularis is characterized by coexistent extensive cutaneous vascular (capillary) and pigmentary anomalies. We describe a 2‐month‐old infant presenting with classic features of phacomatosis pigmentovascularis 2b (phacomatosis cesioflammea). He was also found to have hitherto unreported associations in the form of extensive venous anomalies presenting as striking abdominal wall varicosities and persistent left superior vena cava and natal tooth. 相似文献
998.
999.
1000.